2026 REGISTRATION IS OPEN!
"Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. The data collected is typically used to explain, influence and/or predict health-related outcomes. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data." Digital biomarkers journal
Now in its ninth year hosted in partnership with Roche in Basel, the Digital Biomarkers in Clinical Trials Summit is the first and only global forum of its kind to focus on ways for pharma clinical trials to take advantage of new opportunities to collect better data and improve the patient experience; as well as how these new digital health tools (DHT) supplement existing biomarker strategies.

Join 40+ speakers and advisors, 350 senior-level pharma, clinical trials, technology and digital health executives in-person on June 23, 2026 at Roche Headquarters in Basel to learn, network, develop and improve the way pharma clinical trials utilize mobile-enabled, wearables, and decentralized clinical trial capabilities to improve existing biomarker strategies, improve patient experience and collect better data.

Global experts converge at the forefront of wearable sensor technology, data management, analytics, connected device, decentralized clinical trials & biomarkers strategies in clinical research. If you’re involved with R&D, sales & marketing, information technology, data management, patient recruitment, retention, adherence, artificial intelligence, digital health, digital biomarkers, decentralized trials, quantitative or translational medicine - this is the place to be.

Location
ROCHE BUILDING 1
BASEL, SWITZERLAND
Date & Time
23 June 2026, 08:00 - 18:30 Basel Time (GMT+2)
IN PARTNERSHIP WITH
2026 AGENDA
LATEST DEVELOPMENTS IN
DIGITAL BIOMARKERS

1. Digital Biomarkers in Cardiometabolism

Beyond the more established field of measuring activity levels and other symptoms with DHTs, what additional measurement approaches are being explored within and cardiometabolism?

2. Digital Biomarkers in Neuroscience

Showcasing the biggest impacts Digital Biomarkers have had in Neuroscience clinical development today

3. Digital Biomarkers in Sleep

Exploring burgeoning opportunities for leveraging Digital Measures to uncover insights in Sleep and Cognition

4. Digital Biomarkers in Immunology, Immunotherapy and Ophthalmology

What Digital Biomarker use cases are actively being explored in immunology and immunotherapy? What major advances are coming in the field of ophthalmology?

5. Pushing the Boundaries and Regulatory Path Forward

Are there differences between what can technically be measured and what patients would like us to measure?
What can be done to accelerate Digital Endpoint development?
What role can partnerships between patients, Digital Health Technology (DHT) vendors, clinical trial sites & biopharmaceutical companies play?
What are the challenges within the current regulatory landscape, and how can these be addressed?
2026 Speakers and Advisors
Kara Lassen
SVP, Head of pRED Cardiometabolism DTA
Timothy Kilchenmann
Patient Monitoring Value Stream Lead
Florian Lipsmeier
Digital Biomarker and Remote Patient Management, Data Insights Subchapter Lead
Christian Gossens
Chapter Lead, Digital Biomarkers
Nikolay Manyakov
Sr. Director, Data Science
Adrian Derungs
Data & Analytics Digital Health and Sensor Technology Lead
Sarah Ernst
Head of Clinical Innovation Strategy and Implementation
Sandra Goss
Director, Digital Science Strategy
Bola Grace
Professor of Practice
Isik Karahanoglu
Director, AQDS Group Lead
Arne Müller
AD, Senior Principal Data Scientist, Clinical Digital Endpoints
Valentina Ticcinelli
Biosensors Lead
Frédérique Guilbert
Clinical Strategy Lead for Digital Endpoint
Jonas Dorn
Digital Biomarker Technology Lead
Tom Switzer
Head, Digital Health, gRED Early Clinical Development
Dzmitry Kaliukhovich
Senior Principal Data Scientist II
Erkuden Goikoetxea
Digital Lead, Digital Endpoints
Laura Gaetano
Global Group Head Data Science in Neuroscience
Matteo Lai 
CEO
Abhishek Pratap
Executive Director, Global Evidence Lead
Kirsten Taylor
Expert Scientist and Group Leader, Movement Disorders and Behavioral Biomarkers
Stefan Lambrecht
Principal scientist & Digital Biomarkers Data Analysis Theme Lead, PD
Stijn Rogiers
Head Data Integration and Standards
Ieuan Clay
Director, Science
Werner Popp
Digital Biomarker Science and Technology Lead
Alf Scotland
Neurodegeneration Digital Biomarkers
Ela Bingel-Erlenmeyer
Regulatory Program Lead, Integrated Solutions
Brian Tracey
Senior Director, Statistics
Jingwei Li
Data Scientist
Jane Wells
Global COA Lead
Lada Leyens
EUCAN Regulatory TA Head GI and Inflammation
Marie McCarthy
Digital Endpoint Lead
Katarzyna Wac
Professor, Quality of Life (QoL) Lab
Levi Walrath
Digital Biomarker Strategy Lead
İpek Özer Stillman
VP, Global Head of Health Economics
Aiden Doherty
Professor of Biomedical Informatics
Roy Grossberg
VP, Digital Biomarkers & Partnerships
Yacine Hadjiat
Head, Innovations
Conference Schedule
23 June, 2026

8:30

Welcoming Words & Introduction

Timothy Kilchenmann, Patient Monitoring Value Stream Lead, Roche (Conference Chair)
Christian Gossens, Chapter Lead, Digital Biomarkers, Roche Diagnostics
8:35

Opening Remarks from Roche

Kara Lassen, Senior Vice President, Head of pRED Cardiometabolism DTA, Roche

Session 1

DIGITAL BIOMARKERS IN CARDIOVASCULAR AND CARDIOMETABOLISM

Showcasing the biggest impacts Digital Biomarkers have had on cardiovascular and cardiometabolism in clinical development today
8:50

CASE STUDY: Developing Actigraphy-Derived Measures of Exercise Capacity in Patients with Pulmonary Arterial Hypertension: Lessons Learned

Dzmitry Kaliukhovich, Sr. Principal Data Scientist II, Johnson & Johnson Innovative Medicine
9:05

CASE STUDY: Developing a Novel Digital Endpoint Meaningful to Patients with Cancer Cachexia

Isik Karahanoglu, Director, AQDS Group Lead, Pfizer
9:20

CASE STUDY TBA

Speaker TBA, SkyLabs
9:35

PATIENT SPEAKER TBA
9:50

PANEL DISCUSSION: Digital Biomarkers in Cardiometabolism Today


Beyond the more established field of measuring activity levels and other symptoms with DHTs, what additional measurement approaches are being explored within and cardiometabolism?

Arne Müller, Associate Director, Sr. Principal Data Scientist, Clinical Digital Endpoints, Novartis
Roy Grossberg, VP, Digital Biomarkers & Partnerships, Vivalink
Patient Speaker TBA
Moderated by Adrian Derungs, Data & Analytics Digital Health and Sensor Technology Lead, Roche
10:20

NETWORKING BREAK AND POSTER VIEWING

Session 2

DIGITAL BIOMARKERS IN NEUROSCIENCE

Showcasing the biggest impacts Digital Biomarkers have had in Neuroscience clinical development today
10:55

CASE STUDY: Exploring Minzasolmin and Symptomatic Therapies Effect on Digital Measures Captured by the Verily Study Watch in a subset of the ORCHESTRA Trial participants

Erkuden Goikoetxea, Digital Lead, Digital Endpoints, UCB
Laura Gaetano, Global Group Head Data Science in Neuroscience, Novartis
11:10

CASE STUDY: Parkinson’s Disease Prasinezumab PADOVA Ph2: learnings from using the Roche PD dBM Solution

Kirsten Taylor, Expert Scientist and Group Leader, Movement Disorders and Behavioral Biomarkers, Roche
Stefan Lambrecht, Principal Scientist & Digital Biomarkers Data Analysis Theme Lead, PD, Roche
Werner Popp, Digital Biomarker Science & Technology Lead, Roche
11:25
Presentation TBA


11:40

CASE STUDY: Sensitively Quantifying the loss of Motor Control in Huntington's Disease with the HD Digital Motor Score

Jonas Dorn, Digital Biomarker Technology Lead, Roche


11:55

PANEL DISCUSSION: Digital Biomarkers in Neuroscience Today

• A discussion around the biggest impacts Digital Biomarkers have had in Neuroscience clinical development today
• Progress and evolution of digital biomarkers as primary endpoints in clinical trials

Valentina Ticcinelli, Biosensors Lead, UCB
Abhishek Pratap, Executive Director, Global Evidence Lead, Boehringer Ingelheim
Alf Scotland, Digital Measures, Neurodegeneration, Johnson & Johnson Innovative Medicine
Speaker TBA

Moderated by Florian Lipsmeier, Digital Biomarker and Remote Patient Management, Data Insights Subchapter Lead, Roche
12:20

NETWORKING LUNCH

Session 3

DIGITAL BIOMARKERS IN SLEEP

Exploring burgeoning opportunities for leveraging Digital Measures to uncover insights into Sleep and Cognition
13:20

CASE STUDY: Disease-specific Sleep Biomarkers for Diagnosis and Treatment Monitoring

Brian Tracey, Senior Director, Statistics, Takeda
13:35

CASE STUDY: Hot Flash associated Sleep Disruption and PSA Associated Cognitive Differences in Prostate Cancer

Jingwei Li, Data Scientist, Johnson & Johnson Innovative Medicine

Session 4

DIGITAL BIOMARKERS IN IMMUNOLOGY, RESPIRATORY AND OPHTHALMOLOGY

What Digital Biomarker use cases are actively being explored in immunology and respiratory? What major advances are coming in the field of ophthalmology?
13:50

CASE STUDY: Phase 2 Trial of Upadacitinib in Vitiligo: 3D Imaging Results for Facial Lesions

Sandra Goss, Director, Digital Health Strategy, AbbVie
13:55

CASE STUDY: Building Physiological models of Pain for Clinical Research and Patient Care

Matteo Lai, CEO, Empatica
Yacine Hadjiat, Head, Innovations, Dubai Health
14:15

CASE STUDY: Patients Perspective on daily use of Remote Digital Peakflowmeter in Chronic Respiratory diseases Clinical Trials

Frédérique Guilbert, Clinical Strategy Lead for Digital Endpoint, Sanofi
Jane Wells, Global COA Lead, Sanofi
14:35

PANEL DISCUSSION: Digital Biomarkers in Immunology, Respiratory and Ophthalmology

What Digital Biomarker use cases are actively being explored in immunology and respiratory?
What major advances and opportunities are coming in the field of ophthalmology?

Levi Walrath, Digital Biomarker Lead, Sanofi
Nikolay Manyakov, Sr. Director, Data Science & Digital Health, Johnson & Johnson Innovative Medicine
Speaker TBA

Moderated by Tom Switzer, Head, Digital Health, gRED Early Clinical Development, Genentech
15:00

NETWORKING BREAK AND POSTER VIEWING


Session 5

PUSHING THE BOUNDARIES AND REGULATORY PATH FORWARD

Are there differences between what can technically be measured and what patients would like us to measure?
What can be done to accelerate Digital Endpoint development?
What role can partnerships between patients, Digital Health Technology (DHT) vendors, clinical trial sites & biopharmaceutical companies play?
What are the challenges within the current regulatory landscape, and how can these be addressed?
15:30

Developing Time-series Machine Learning Methods to Unlock New Insights from Large-Scale Biomedical Resources

Aiden Doherty, Professor of Biomedical Informatics, University of Oxford
15:45

CASE STUDY: Unlocking the Value of Patient-Centered Digital Measures

Ieuan Clay, Director, Science, Vivosense
Stijn Rogiers, Head, Data Integration and Standards, Argenx
16:00

PANEL DISCUSSION: Digital Measures of Quality of Life

İpek Özer Stillman, VP, Global Head of Health Economics, Takeda
Bola Grace, Professor of Practice, UCL
Speaker TBA, Patient Centered Outcome Research, Roche
Patient Speaker TBA

Moderated by Katarzyna Wac, Professor, Quality of Life Lab, University of Geneva
16:25

PANEL DISCUSSION: The Regulatory Path Forward

• Progress with shaping the ecosystem to optimise digital measures development and adoption in medicine development and registration

Lada Leyens, EUCAN Regulatory TA Head GI and Inflammation, Takeda
Marie McCarthy, Digital Endpoint Lead, Novartis
Thorsten Vetter, EMA (invited)
FDA Representative (invited)

Moderated by Ela Bingel-Erlenmeyer, Regulatory Program Lead - Integrated Solutions, Digital - Devices - Diagnostics, Roche
16:55

CONCLUDING REMARKS AND REFLECTIONS

Key takeaways and next steps from all stakeholders within the digital measures community

Timothy Kilchenmann, Patient Monitoring Value Stream Lead, Roche (Conference Chair)
Christian Gossens, Chapter Lead, Digital Biomarkers, Roche Diagnostics
17:00 - 18:30

NETWORKING APÉRO

Sponsored by:

Sponsors & Exhibitors

HOST SPONSOR
GOLD SPONSOR
GOLD SPONSOR
GOLD SPONSOR
SILVER SPONSOR
EXHIBITOR
EXHIBITOR
EXHIBITOR
EXHIBITOR
EXHIBITOR
EXHIBITOR
EXHIBITOR
SUPPORTING SPONSOR
SUPPORTING SPONSOR
SUPPORTING SPONSOR
Did you miss the Digital Biomarkers Summit?
Sign up below for the complete video coverage and slide decks from each session of the conference.
SEND ME THE PROCEEDINGS!
Digital Biomarkers Summit 2020
Teaser Video
Interested in Sponsorship & Exhibition Opportunities?
Inquire Here
2021 Conference Presentations
Paulo Fontoura
ROCHE
Paulo Fontoura, Christian Gossens, Jennifer Goldsack, Ruth Schneider, Fai Ng
Roche, DIME, Chet, Newcastle University
Ruth Schneider & Larsson Omberg
CHET & Sage Bionetworks
Florian Lipsmeier
ROCHE
Brian Tracey
Takeda
Kate Lyden
VIVOSENSE
Steve Steinhubl, Jian Yang, Mark Sapp, Tom Switzer
PHYSIQ, ELI LILLY & CO, JANSSEN & GENENTECH
Diane Stephenson, Arne Müller, Matt Biggs & Lauren Oliva
C-PATH, NOVARTIS, ACTIGRAPH & BIOGEN
2020 Conference Presentations
Christian Gossens
ROCHE
Keynote Panel
Roche, Abbvie, Chet, biogen
Ray Dorsey
CHET
Michelle Crouthamel
AbbVie
Kate Lyden & Jeremy Wyatt
Vivosense & ACtigraph
Sohini Chowdhury
MJFF
Nikhil Mahadevan & Yiorgos Christakis
pfizer
Matt Pipke
physiq
Kirsten Taylor, Florian Lipsmeier & Hannah Staunton
roche
Concluding Panel
Mjff, Novartis, roche, Pfizer & vivosense
2019 Conference Presentations
Bryn Roberts
ROCHE
Dan Karlin
HEALTHMODE
Timothy Kilchenmann
ROCHE
Valentin Hamy
GSK
Emilio Merlo Pich
TAKEDA
Ben Vandendriessche
BYTEFLIES
Peter Groenen
IDORSIA
Michelle Longmire
MEDABLE
Ieuan Clay
NOVARTIS
Valeria De Luca
Novartis
Sohini Chowdhury
Michael J FOx Foundation for Parkinson's Research
Arne Müller
NOVARTIS
Conference Highlights from the 2019 Digital Biomarkers Summit hosted at Roche
Conference Photo Gallery
Venue
Hosted in Partnership with Roche
Roche-Turm (Bau 1), Grenzacherstrasse 124, 4070 Basel, Switzerland
The office high-rise, Building 1, is a key pillar of Roche's site development strategy. With its straightforward yet unmistakable design, it blends in perfectly with the Roche grounds and the Basel cityscape. With 41 floors and workspace for around 2,000 employees, the office high-rise also shows a clear commitment to the Basel site.
Reserve Your Room


Hotel Room Block

Hyperion Hotel Basel

(4 Star Hotel) Hyperion Hotel Basel in Basel, Switzerland
Location: Messepl. 12, 4058 Basel, Switzerland

In Basel's tallest habitable building, the HYPERION Hotel Basel is next to the Basel Messe trade fair center and just a short walk from the Old Town. It offers a sauna and a fitness center. Each of the 224 non-smoking guest rooms offers panoramic views of the city, free WiFi, air conditioning, refreshing bath products, a safe, hair dryer, and flat-screen TV with Sky channels.

PanAgora Pharma has a conference room block at the Hyperion Hotel Basel - just 1km from Roche Building 1. To book your room at the preferred room block rate, please use this link: DBM Summit Room Block at Hyperion Hotel Basel

***The Room Block will open on 15 March 2026, and close on 13 May 2026, so we encourage all attendees staying in Basel to please make your reservation before then. Spaces are limited and once the block fills, it is closed.
 Don't Miss the Digital Biomarkers in Clinical Trials Summit 2026!
Where the Industry Meets to Accelerate the Development of Digital Biomarkers
Register Now
© 2026 PanAgora Pharma, a division of PanAgora Conference Group, LLC.  All Rights Reserved.
CONTACT US

Processing Registration...